{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:19:38Z","timestamp":1784805578668,"version":"3.55.0"},"reference-count":163,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.drudis.2025.104451","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T23:34:55Z","timestamp":1754955295000},"page":"104451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Future potential therapeutics to treat MASH"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3322-820X","authenticated-orcid":false,"given":"Shriram","family":"Mahajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7230-122X","authenticated-orcid":false,"given":"Navya","family":"Malladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0008-0480","authenticated-orcid":false,"given":"Sanjay K.","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104451_b0005","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104451_b0010","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.drudis.2025.104451_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100727","article-title":"The epidemiology of non-alcoholic steatohepatitis (NASH) in the United States between 2010\u20132020: a population-based study","volume":"27","author":"Hamid","year":"2022","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.drudis.2025.104451_b0020","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.29721","article-title":"Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis","volume":"68","author":"Younossi","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2025.104451_b0025","unstructured":"US Food and Drug Administration. FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease. Published March 14, 2024. Accessed November 25, 2024."},{"key":"10.1016\/j.drudis.2025.104451_b0030","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2025.104451_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101143","article-title":"Metabolic drivers of non-alcoholic fatty liver disease","volume":"50","author":"Bence","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.drudis.2025.104451_b0040","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104451_b0045","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104451_b0050","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41392-022-01070-3","article-title":"Targeting fibrosis: mechanisms and clinical trials","volume":"7","author":"Zhao","year":"2022","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.drudis.2025.104451_b0055","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2025.104451_b0060","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MPG.0000000000001482","article-title":"NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children","volume":"64","author":"Vos","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.drudis.2025.104451_b0065","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s13105-023-00954-4","article-title":"Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment","volume":"79","author":"Sangro","year":"2023","journal-title":"J Physiol Biochem"},{"key":"10.1016\/j.drudis.2025.104451_b0070","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2025.104451_b0075","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2025.104451_b0080","article-title":"Targeting thyroid hormone\/thyroid hormone receptor axis: an attractive therapy strategy in liver diseases","volume":"13","author":"Tang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2025.104451_b0085","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3803\/EnM.2024.203","article-title":"Selective agonists of thyroid hormone receptor beta: promising tools for the treatment of nonalcoholic fatty liver disease","volume":"39","author":"Cho","year":"2024","journal-title":"Endocrinol Metab"},{"key":"10.1016\/j.drudis.2025.104451_b0090","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1111\/bph.15427","article-title":"Activation of thyroid hormone receptor-\u03b2 improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis","volume":"178","author":"Kannt","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2025.104451_b0095","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1021\/acs.jmedchem.2c01669","article-title":"Discovery of highly potent and selective thyroid hormone receptor \u03b2 agonists for the treatment of nonalcoholic steatohepatitis","volume":"66","author":"Hu","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104451_b0100","article-title":"KYLO-0603, a novel liver-targeting, thyroid hormone receptor-\u03b2 agonist for the treatment of MASH","author":"Lu","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.drudis.2025.104451_b0105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.biochi.2016.11.009","article-title":"PPARs and nonalcoholic fatty liver disease","volume":"136","author":"Liss","year":"2017","journal-title":"Biochimie"},{"key":"10.1016\/j.drudis.2025.104451_b0110","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.3390\/ijms23084305","article-title":"PPAR-targeted therapies in the treatment of non-alcoholic fatty liver disease in diabetic patients","volume":"23","author":"Lange","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104451_b0115","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jceh.2021.06.015","article-title":"Saroglitazar for nonalcoholic fatty liver disease: a single centre experience in 91 patients","volume":"12","author":"Padole","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.drudis.2025.104451_b0120","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.3390\/ijms20205055","article-title":"Exploration and development of PPAR modulators in health and disease: an update of clinical evidence","volume":"20","author":"Cheng","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104451_b0125","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3390\/biom13081264","article-title":"Current clinical trial status and future prospects of PPAR-targeted drugs for treating nonalcoholic fatty liver disease","volume":"13","author":"Kamata","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2025.104451_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.615409","article-title":"Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis","volume":"12","author":"Lian","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.drudis.2025.104451_b0135","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1002\/hep4.1993","article-title":"Combination of tofogliflozin and pioglitazone for NAFLD: extension to the ToPiND randomized controlled trial","volume":"6","author":"Yoneda","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.drudis.2025.104451_b0140","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/2044090","article-title":"Effect and safety of pioglitazone-metformin tablets in the treatment of newly diagnosed type 2 diabetes patients with nonalcoholic fatty liver disease in Shaanxi Province: a randomized, double-blinded, double-simulated multicenter study","volume":"2023","author":"Jianfang","year":"2023","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.drudis.2025.104451_b0145","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/dom.16049","article-title":"Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes\u2014a real-world study","volume":"7","author":"Lee","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.drudis.2025.104451_b0150","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.drudis.2025.104451_b0155","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104451_b0160","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2.4\u00a0mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2025.104451_b0165","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104451_b0170","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.cgh.2023.06.004","article-title":"Glucagon-like Peptide-1 Receptor agonist use in patients with liver cirrhosis and type 2 diabetes","volume":"22","author":"Yen","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2025.104451_b0175","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/clinem\/dgab578","article-title":"The emerging role of Glucagon-like Peptide-1 Receptor agonists for the management of NAFLD","volume":"107","author":"Patel Chavez","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.drudis.2025.104451_b0180","unstructured":"Novo Nordisk A\/S. The Effect of Semaglutide in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis. https:\/\/clinicaltrials.gov\/study\/NCT04822181. Published March 26, 2021. Accessed November 25, 2024."},{"key":"10.1016\/j.drudis.2025.104451_b0185","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104451_b0190","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R\/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat Metab"},{"key":"10.1016\/j.drudis.2025.104451_b0195","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104451_b0200","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104451_b0205","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The fibroblast growth factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"key":"10.1016\/j.drudis.2025.104451_b0210","doi-asserted-by":"crossref","first-page":"14158","DOI":"10.1073\/pnas.1009427107","article-title":"Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19)","volume":"107","author":"Wu","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2025.104451_b0215","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/joim.12993","article-title":"Fructose metabolism as a common evolutionary pathway of survival associated with climate change, food shortage and droughts","volume":"287","author":"Johnson","year":"2020","journal-title":"J Intern Med"},{"key":"10.1016\/j.drudis.2025.104451_b0220","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2025.104451_b0225","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2025.104451_b0230","article-title":"A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis","volume":"5","author":"Harrison","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.drudis.2025.104451_b0235","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S2468-1253(22)00347-8","article-title":"Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b\/2a multiple-ascending-dose study","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2025.104451_b0240","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF21 agonists: an emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2025.104451_b0245","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2024.02.022","article-title":"Safety and efficacy of efruxifermin in combination with a GLP-1 receptor agonist in patients with NASH\/MASH and type 2 diabetes in a randomized phase 2 study","volume":"23","author":"Harrison","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2025.104451_b0250","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6\u03b1-Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104451_b0255","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104451_b0260","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S1097-2765(03)00112-6","article-title":"Structural basis for bile acid binding and activation of the nuclear receptor FXR","volume":"11","author":"Mi","year":"2003","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2025.104451_b0265","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(19)32963-0","article-title":"Obeticholic acid: towards first approval for NASH","volume":"394","author":"Eslam","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104451_b0270","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study","volume":"76","author":"Rinella","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2025.104451_b0275","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines","volume":"67","author":"Hirschfield","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.drudis.2025.104451_b0280","doi-asserted-by":"crossref","first-page":"9201","DOI":"10.1021\/acs.jmedchem.6b01126","article-title":"Discovery of 3\u03b1,7\u03b1,11\u03b2-trihydroxy-6\u03b1-ethyl-5\u03b2-cholan-24-oic acid (TC-100), a novel bile acid as potent and highly selective FXR agonist for enterohepatic disorders","volume":"59","author":"Pellicciari","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104451_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113380","article-title":"Farnesoid X receptor activation by the novel agonist TC-100 (3\u03b1, 7\u03b1, 11\u03b2-trihydroxy-6\u03b1-ethyl-5\u03b2-cholan-24-oic acid) preserves the intestinal barrier integrity and promotes intestinal microbial reshaping in a mouse model of obstructed bile acid flow","volume":"153","author":"Marzano","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.drudis.2025.104451_b0290","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","article-title":"EDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study","volume":"76","author":"Ratziu","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2025.104451_b0295","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2023.07.034","article-title":"FXR agonists in NASH treatment","volume":"79","author":"Adorini","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2025.104451_b0300","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1128\/MCB.01122-06","article-title":"Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice","volume":"27","author":"Harada","year":"2017","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.drudis.2025.104451_b0305","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cmet.2017.07.009","article-title":"Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation","volume":"26","author":"Kim","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.drudis.2025.104451_b0310","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2025.104451_b0315","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jcmgh.2020.06.001","article-title":"Acetyl-CoA carboxylase inhibition improves multiple dimensions of NASH pathogenesis in model systems","volume":"10","author":"Ross","year":"2020","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2025.104451_b0320","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/nm.3704","article-title":"De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells","volume":"20","author":"Berod","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2025.104451_b0325","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2020.04.037","article-title":"Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation","volume":"73","author":"Bates","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2025.104451_b0330","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41401-019-0310-0","article-title":"WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice","volume":"41","author":"Gao","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.drudis.2025.104451_b0335","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/13543784.2020.1668374","article-title":"GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)","volume":"29","author":"Alkhouri","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.drudis.2025.104451_b0340","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbrc.2008.03.063","article-title":"17beta-Hydroxysteroid dehydrogenase type 13 is a liver-specific lipid droplet-associated protein","volume":"370","author":"Horiguchi","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2025.104451_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108428","article-title":"17\u03b2-Hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease","volume":"246","author":"Wang","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.drudis.2025.104451_b0350","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.3390\/ijms23105544","article-title":"Down-regulating the high level of 17-beta-hydroxysteroid dehydrogenase 13 plays a therapeutic role for non-alcoholic fatty liver disease","volume":"23","author":"Wang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104451_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100514","article-title":"Evaluation of antisense oligonucleotide therapy targeting Hsd17b13 in a fibrosis mice model","volume":"65","author":"Ma","year":"2024","journal-title":"J Lipid Res"},{"key":"10.1016\/j.drudis.2025.104451_b0360","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jhep.2023.05.007","article-title":"Therapeutic opportunities for the treatment of NASH with genetically validated targets","volume":"79","author":"Lind\u00e9n","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2025.104451_b0365","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2022.11.025","article-title":"A phase I\/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis","volume":"78","author":"Mak","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2025.104451_b0370","article-title":"Phase 1 study of the RNA interference therapeutic ALN-HSD in healthy adults and patients with non-alcoholic steatohepatitis","author":"Sanyal","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2025.104451_b0375","unstructured":"Alnylam Pharmaceuticals. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 3-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH). https:\/\/clinicaltrials.gov\/study\/NCT04565717. Published September 22, 2020. Updated May 17, 2024. Accessed November 25, 2024."},{"key":"10.1016\/j.drudis.2025.104451_b0380","unstructured":"Regeneron Pharmaceuticals. A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition (NASHGEN-2). https:\/\/clinicaltrials.gov\/study\/NCT05519475. Published August 26, 2022. Updated July 30, 2025. Accessed November 25, 2024."},{"key":"10.1016\/j.drudis.2025.104451_b0385","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1021\/acs.jmedchem.4c02720","article-title":"Discovery of first-in-class FXR and HSD17B13 dual modulator for the treatment of metabolic dysfunction-associated fatty liver disease","volume":"68","author":"Jiao","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104451_b0390","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on SGLT2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.drudis.2025.104451_b0395","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/hep4.1611","article-title":"Impact of Sodium Glucose Cotransporter 2 inhibitors on nonalcoholic fatty liver disease complicated by diabetes mellitus","volume":"5","author":"Zhang","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.drudis.2025.104451_b0400","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/s41598-024-52603-5","article-title":"Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis","volume":"14","author":"Ong Lopez","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104451_b0405","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.drudis.2025.104451_b0410","article-title":"Efficacy of SGLT2 inhibitors versus pioglitazone in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review","volume":"15","author":"Kaur","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.drudis.2025.104451_b0415","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.635556","article-title":"Effect of SGLT2 inhibitors on type 2 diabetes mellitus with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"12","author":"Wei","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.drudis.2025.104451_b0420","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3390\/medicina59061136","article-title":"The effects of Sodium-Glucose Cotransporter 2 inhibitors on steatosis and fibrosis in patients with non-alcoholic fatty liver disease or steatohepatitis and type 2 diabetes: a systematic review of randomized controlled trials","volume":"59","author":"Bica","year":"2023","journal-title":"Medicina"},{"key":"10.1016\/j.drudis.2025.104451_b0425","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12933-024-02461-2","article-title":"Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case\u2013control study","volume":"23","author":"Chang","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.drudis.2025.104451_b0430","article-title":"Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: study protocol for a randomized clinical trial","volume":"19","author":"Lin","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104451_b0435","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1007\/s00535-024-02158-z","article-title":"Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan","volume":"59","author":"Kawaguchi","year":"2024","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.drudis.2025.104451_b0440","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3390\/pharmaceutics15071963","article-title":"Pharmaceutical strategies to improve druggability of potential drug candidates in nonalcoholic fatty liver disease therapy","volume":"15","author":"Amatya","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2025.104451_b0445","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial","volume":"389","author":"Lin","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.drudis.2025.104451_b0450","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000040356","article-title":"The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: a randomized controlled trial","volume":"103","author":"Khaliq","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.drudis.2025.104451_b0455","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12902-025-01882-8","article-title":"The effect of empagliflozin on non-alcoholic fatty liver disease-related parameters in patients with type 2 diabetes mellitus: a randomized controlled trial","volume":"25","author":"Shojaei","year":"2025","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.drudis.2025.104451_b0460","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1210\/clinem\/dgad249","article-title":"Canagliflozin and metabolic associated fatty liver disease in patients with diabetes mellitus: new insights from CANVAS","volume":"108","author":"Borisov","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.drudis.2025.104451_b0465","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/0113892002290055240212074758","article-title":"Recent advances in hepatic metabolic regulation by the nuclear factor Rev-erb\u03b1","volume":"25","author":"Zhang","year":"2024","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.drudis.2025.104451_b0470","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/s41401-022-00883-w","article-title":"The role of REV-ERB in NASH","volume":"43","author":"Griffett","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.drudis.2025.104451_b0475","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jhep.2024.07.034","article-title":"Targeting the liver clock improves fibrosis by restoring TGF-\u03b2 signaling","volume":"82","author":"Crouchet","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.drudis.2025.104451_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117845","article-title":"Regulation of exercise ability and glycolipid metabolism by synthetic SR9009 analogues as new REV-ERB-\u03b1 agonists","volume":"111","author":"Li","year":"2024","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2025.104451_b0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236000","article-title":"REV-ERB agonism improves liver pathology in a mouse model of NASH","volume":"15","author":"Griffett","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104451_b0490","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.livres.2024.03.002","article-title":"Targeting nuclear receptors for NASH\/MASH: from bench to bedside","volume":"8","author":"Sinha","year":"2024","journal-title":"Liver Res"},{"key":"10.1016\/j.drudis.2025.104451_b0495","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.livres.2023.07.002","article-title":"Retinoic acid signaling in fatty liver disease","volume":"7","author":"Bawa","year":"2023","journal-title":"Liver Res"},{"key":"10.1016\/j.drudis.2025.104451_b0500","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s43066-019-0014-7","article-title":"Comparison between NAFLD fibrosis score and retinoic acid serum level in NAFLD","volume":"10","author":"Allam","year":"2020","journal-title":"Egyptian Liver J"},{"key":"10.1016\/j.drudis.2025.104451_b0505","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/oby.23929","article-title":"Adipocyte retinoic acid receptor \u03b1 prevents obesity and steatohepatitis by regulating energy expenditure and lipogenesis","volume":"32","author":"Cassim Bawa","year":"2024","journal-title":"Obesity"},{"key":"10.1016\/j.drudis.2025.104451_b0510","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00109-016-1434-z","article-title":"A retinoic acid receptor \u03b22 agonist reduces hepatic stellate cell activation in nonalcoholic fatty liver disease","volume":"94","author":"Trasino","year":"2016","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.drudis.2025.104451_b0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101331","article-title":"A retinoic acid receptor \u03b22 agonist attenuates transcriptome and metabolome changes underlying nonalcohol-associated fatty liver disease","volume":"297","author":"Tang","year":"2021","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2025.104451_b0520","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.3748\/wjg.v26.i38.5812","article-title":"Is vitamin D receptor a druggable target for non-alcoholic steatohepatitis?","volume":"26","author":"Cao","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.drudis.2025.104451_b0525","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/jgh3.12010","article-title":"Vitamin D supplementation in patients with nonalcoholic fatty liver disease: a randomized controlled trial","volume":"1","author":"Sakpal","year":"2017","journal-title":"JGH Open"},{"key":"10.1016\/j.drudis.2025.104451_b0530","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","article-title":"Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD","volume":"47","author":"Coyne","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.drudis.2025.104451_b0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2024.111299","article-title":"Paricalcitol attenuates oxidative stress and inflammatory response in the liver of NAFLD rats by regulating FOXO3a and NF\u03baB acetylation","volume":"121","author":"Malladi","year":"2024","journal-title":"Cell Signal"},{"key":"10.1016\/j.drudis.2025.104451_b0540","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/iep.12519","article-title":"Enhanced hepatoprotective effects of empagliflozin and vitamin D dual therapy against metabolic dysfunction-associated steatohepatitis in mice by boosted modulation of metabolic, oxidative stress, and inflammatory pathways","volume":"105","author":"Farrash","year":"2024","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.drudis.2025.104451_b0545","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/MEG.0000000000002653","article-title":"Steatosis regression assessed by cap after Vitamin \u2018D\u2019 supplementation in NAFLD patients with Vitamin \u2018D\u2019 deficiency","volume":"36","author":"Emam","year":"2024","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2025.104451_b0550","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12937-024-00911-x","article-title":"Effects of vitamin D supplementation on liver fibrogenic factors, vitamin D receptor and liver fibrogenic microRNAs in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: an exploratory randomized clinical trial","volume":"23","author":"Ebrahimpour-Koujan","year":"2024","journal-title":"Nutr J"},{"key":"10.1016\/j.drudis.2025.104451_b0555","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3390\/ijms17101712","article-title":"MicroRNA in control of gene expression: an overview of nuclear functions","volume":"17","author":"Catalanotto","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104451_b0560","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/sj.bjc.6603023","article-title":"MicroRNAs in cell proliferation, cell death, and tumorigenesis","volume":"94","author":"Hwang","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drudis.2025.104451_b0565","doi-asserted-by":"crossref","first-page":"6176","DOI":"10.1038\/sj.onc.1209912","article-title":"miRNAs and apoptosis: RNAs to die for","volume":"25","author":"Jovanovic","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2025.104451_b0570","doi-asserted-by":"crossref","first-page":"15330","DOI":"10.1073\/pnas.1207605109","article-title":"Control of mitochondrial metabolism and systemic energy homeostasis by microRNAs 378 and 378*","volume":"109","author":"Carrer","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2025.104451_b0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101581","article-title":"MicroRNAs in non-alcoholic fatty liver disease: progress and perspectives","volume":"65","author":"Hochreuter","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.drudis.2025.104451_b0580","doi-asserted-by":"crossref","first-page":"13729","DOI":"10.1038\/srep13729","article-title":"Effect of miR-34a in regulating steatosis by targeting PPAR\u03b1 expression in nonalcoholic fatty liver disease","volume":"5","author":"Ding","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104451_b0585","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/hep.31423","article-title":"Liver X receptor alpha activation inhibits autophagy and lipophagy in hepatocytes by dysregulating autophagy-related 4B cysteine peptidase and Rab-8B, reducing mitochondrial fuel oxidation","volume":"73","author":"Kim","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2025.104451_b0590","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1136\/gutjnl-2014-308883","article-title":"Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPAR\u03b1 expression","volume":"65","author":"Loyer","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.drudis.2025.104451_b0595","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1136\/gutjnl-2015-310822","article-title":"Stress-activated miR-21\/miR-21* in hepatocytes promotes lipid and glucose metabolic disorders associated with high-fat diet consumption","volume":"65","author":"Calo","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.drudis.2025.104451_b0600","doi-asserted-by":"crossref","DOI":"10.1172\/JCI141513","article-title":"Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223-enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis","volume":"131","author":"He","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2025.104451_b0605","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.31658","article-title":"Myeloid-cell-specific IL-6 signaling promotes microRNA-223-enriched exosome production to attenuate NAFLD-associated fibrosis","volume":"74","author":"Hou","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.drudis.2025.104451_b0610","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.cmet.2020.12.019","article-title":"MiR-690, an exosomal-derived miRNA from M2-polarized macrophages, improves insulin sensitivity in obese mice","volume":"33","author":"Ying","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.drudis.2025.104451_b0615","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.cmet.2022.05.008","article-title":"MiR-690 treatment causes decreased fibrosis and steatosis and restores specific Kupffer cell functions in NASH","volume":"34","author":"Gao","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.drudis.2025.104451_b0620","doi-asserted-by":"crossref","first-page":"11874","DOI":"10.1038\/s41598-018-30349-1","article-title":"Ursodeoxycholic acid improves liver function via phenylalanine\/tyrosine pathway and microbiome remodelling in patients with liver dysfunction","volume":"8","author":"Kim","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104451_b0625","doi-asserted-by":"crossref","DOI":"10.1177\/03000605231197058","article-title":"Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review","volume":"51","author":"Kan Changez","year":"2023","journal-title":"J Int Med Res"},{"key":"10.1016\/j.drudis.2025.104451_b0630","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/bs.pmbts.2023.12.005","article-title":"An update on the therapeutic role of RNAi in NAFLD\/NASH","volume":"204","author":"Dehghan","year":"2024","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/j.drudis.2025.104451_b0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101198","article-title":"A gene silencing-based approach to tackle fatty liver disease","volume":"32","author":"Strnad","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.drudis.2025.104451_b0640","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2022.01.038","article-title":"Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis","volume":"343","author":"Zhou","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2025.104451_b0645","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41392-022-00974-4","article-title":"Microbiota in health and diseases","volume":"7","author":"Hou","year":"2022","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.drudis.2025.104451_b0650","article-title":"Faecalibacterium prausnitzii prevents hepatic damage in a mouse model of NASH induced by a high-fructose high-fat diet","volume":"14","author":"Shin","year":"2013","journal-title":"Front Microbiol"},{"key":"10.1016\/j.drudis.2025.104451_b0655","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.1003755","article-title":"Gut microbiome and microbial metabolites in NAFLD and after bariatric surgery: correlation and causality","volume":"13","author":"Xia","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.drudis.2025.104451_b0660","article-title":"Current status of probiotic and related health benefits","volume":"2","author":"Das","year":"2002","journal-title":"Appl Food Res"},{"key":"10.1016\/j.drudis.2025.104451_b0665","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.3390\/jcm11144119","article-title":"Fecal microbiota transplantation as new therapeutic avenue for human diseases","volume":"11","author":"Biazzo","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.drudis.2025.104451_b0670","unstructured":"Promrat K. Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis (NASH). A Pilot Study. https:\/\/clinicaltrials.gov\/study\/NCT02469272. Published June 9, 2015. Accessed November 25, 2024."},{"key":"10.1016\/j.drudis.2025.104451_b0675","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3390\/medicina58111559","article-title":"Fecal microbiota transplantation in NAFLD treatment","volume":"58","author":"Abenavoli","year":"2022","journal-title":"Medicina"},{"key":"10.1016\/j.drudis.2025.104451_b0680","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00535-019-01649-8","article-title":"Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives","volume":"55","author":"Hu","year":"2020","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.drudis.2025.104451_b0685","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.ebiom.2019.05.066","article-title":"Fecal microbiota transplantation beyond Clostridioides difficile infections","volume":"44","author":"Wortelboer","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.drudis.2025.104451_b0690","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/apt.12758","article-title":"Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis","volume":"39","author":"Alisi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.drudis.2025.104451_b0695","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/MPG.0000000000001422","article-title":"Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents","volume":"64","author":"Famouri","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.drudis.2025.104451_b0700","article-title":"Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis\u2014a longitudinal study","volume":"8","author":"Wong","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104451_b0705","doi-asserted-by":"crossref","first-page":"418","DOI":"10.23736\/S0026-4806.18.05845-7","article-title":"Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study","volume":"109","author":"Kobyliak","year":"2018","journal-title":"Minerva Med"},{"key":"10.1016\/j.drudis.2025.104451_b0710","doi-asserted-by":"crossref","first-page":"41","DOI":"10.15403\/jgld.2014.1121.271.kby","article-title":"A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial","volume":"27","author":"Kobyliak","year":"2018","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.drudis.2025.104451_b0715","first-page":"101","article-title":"Efficacy of probiotics on the treatment of non-alcoholic fatty liver disease","volume":"57","author":"Wang","year":"2018","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.drudis.2025.104451_b0720","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/1751-2980.12561","article-title":"Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: a pilot trial","volume":"18","author":"Manzhalii","year":"2017","journal-title":"J Dig Dis"},{"key":"10.1016\/j.drudis.2025.104451_b0725","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1080\/07315724.2015.1031355","article-title":"Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: a double-blind randomized clinical trial","volume":"35","author":"Sepideh","year":"2016","journal-title":"J Am Coll Nutr"},{"key":"10.1016\/j.drudis.2025.104451_b0730","first-page":"1090","article-title":"Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial","volume":"15","author":"Aller","year":"2011","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.drudis.2025.104451_b0735","doi-asserted-by":"crossref","first-page":"7386","DOI":"10.3168\/jds.2014-8500","article-title":"Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease","volume":"97","author":"Nabavi","year":"2014","journal-title":"J Dairy Sci"},{"key":"10.1016\/j.drudis.2025.104451_b0740","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.yexcr.2014.04.017","article-title":"Human mesenchymal stem cells towards non-alcoholic steatohepatitis in an immunodeficient mouse model","volume":"326","author":"Winkler","year":"2014","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.drudis.2025.104451_b0745","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.bbrc.2016.12.125","article-title":"Adipose-derived mesenchymal stem cells ameliorate hyperglycemia through regulating hepatic glucose metabolism in type 2 diabetic rats","volume":"483","author":"Xie","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2025.104451_b0750","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13287-015-0201-3","article-title":"Adipose-derived mesenchymal stem cells improve glucose homeostasis in high-fat diet-induced obese mice","volume":"6","author":"Cao","year":"2015","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.drudis.2025.104451_b0755","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s43587-022-00348-z","article-title":"Age-related liver endothelial zonation triggers steatohepatitis by inactivating pericentral endothelium-derived C-kit","volume":"3","author":"Duan","year":"2023","journal-title":"Nat Aging"},{"key":"10.1016\/j.drudis.2025.104451_b0760","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/s12951-021-01120-y","article-title":"Cargo proteins in extracellular vesicles: potential for novel therapeutics in non-alcoholic steatohepatitis","volume":"19","author":"Kim","year":"2021","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.drudis.2025.104451_b0765","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1186\/s13287-022-03201-7","article-title":"Human umbilical cord mesenchymal stromal cell-derived exosomes protect against MCD-induced NASH in a mouse model","volume":"13","author":"Shi","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.drudis.2025.104451_b0770","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8628027","article-title":"Human umbilical cord-derived mesenchymal stem cell therapy ameliorates nonalcoholic fatty liver disease in obese Type 2 diabetic mice","volume":"2019","author":"Li","year":"2019","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.drudis.2025.104451_b0775","article-title":"Human umbilical cord mesenchymal stem cells attenuate diet-induced obesity and NASH-related fibrosis in mice","volume":"10","author":"Hu","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.drudis.2025.104451_b0780","doi-asserted-by":"crossref","first-page":"18778","DOI":"10.1038\/s41598-021-98254-8","article-title":"Conditioned medium from stem cells derived from human exfoliated deciduous teeth ameliorates NASH via the gut\u2013liver axis","volume":"11","author":"Muto","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104451_b0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114686","article-title":"Limosilactobacillus fermentum role in combination with human mesenchymal stem cell-derived secretome: a novel approach to alleviate inflammation in NASH pathogenesis","volume":"156","author":"Mahmoudi","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.drudis.2025.104451_b0790","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104451_b0795","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/apt.17734","article-title":"Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis","volume":"59","author":"Harrison","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.drudis.2025.104451_b0800","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104451_b0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2019.06.017","article-title":"REGENERATE: design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis","volume":"84","author":"Ratziu","year":"2019","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.drudis.2025.104451_b0810","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/apt.18331","article-title":"Semaglutide 2.4\u2009mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial","volume":"60","author":"Newsome","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.drudis.2025.104451_b0815","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625001643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625001643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T23:38:07Z","timestamp":1757115487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625001643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":163,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1359644625001643"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104451","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Future potential therapeutics to treat MASH","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104451","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104451"}}